Abstract Background Myeloproliferative neoplasms (MPNs) are hematopoietic stem cell
neoplasms with a high risk of thrombosis, including acute myocardial infarction (AMI) …

Simple Summary Patients with chronic myeloproliferative neoplasms (MPNs) such as
polycythemia vera and essential thrombocythemia have an elevated risk of acute leukemia …

Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera.
However, estimates of its effect in terms of clinical outcomes (thrombosis, bleeding …

Background Circulating blasts (peripheral blood [PB] blasts)≥ 1% have long been
considered an unfavorable feature for patients with primary myelofibrosis. Whether further …

The diagnosis of myeloproliferative neoplasms (MPN) requires the integration of clinical,
morphological, genetic and immunophenotypic findings. Recently, there has been a …

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical
course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but …

Classical Philadelphia-negative myeloproliferative neoplasms (MPNs) are clonal
hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of …

Allogeneic hematopoietic cell transplantation (allo‐HCT) is increasingly used in older
myelofibrosis (MF) patients, but its risk/benefit ratio compared to non‐transplant approaches …

Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are clonal
disorders of a hematopoietic stem cell, characterized by an abnormal proliferation of largely …

According to the current treatment recommendations, anagrelide, an oral antiplatelet agent,
is recommended as a second-line therapy for patients with high-risk essential …